Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Non-Current Deffered Revenue: 2017-2022

Historic Non-Current Deffered Revenue for Denali Therapeutics (DNLI) over the last 5 years, with Dec 2022 value amounting to $479,000.

  • Denali Therapeutics' Non-Current Deffered Revenue fell 85.90% to $479,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $479,000, marking a year-over-year decrease of 85.90%. This contributed to the annual value of $479,000 for FY2022, which is 85.90% down from last year.
  • Latest data reveals that Denali Therapeutics reported Non-Current Deffered Revenue of $479,000 as of Q4 2022, which was down 85.90% from $3.4 million recorded in Q2 2022.
  • Denali Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $57.4 million during Q4 2018, with a 5-year trough of $479,000 in Q4 2022.
  • Over the past 3 years, Denali Therapeutics' median Non-Current Deffered Revenue value was $19.7 million (recorded in 2020), while the average stood at $18.1 million.
  • In the last 5 years, Denali Therapeutics' Non-Current Deffered Revenue soared by 811.19% in 2018 and then crashed by 89.15% in 2022.
  • Quarterly analysis of 5 years shows Denali Therapeutics' Non-Current Deffered Revenue stood at $57.4 million in 2018, then declined by 23.71% to $43.8 million in 2019, then tumbled by 46.69% to $23.3 million in 2020, then crashed by 85.43% to $3.4 million in 2021, then crashed by 85.90% to $479,000 in 2022.
  • Its Non-Current Deffered Revenue was $479,000 in Q4 2022, compared to $3.4 million in Q2 2022 and $3.4 million in Q1 2022.